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ORIGINAL ARTICLE
Benzimidazole-based derivatives as privileged scaffold developed for the
treatment of the RSV infection: a computational study exploring the potency
and cytotoxicity profiles
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Paola Fossaa
aDepartment of Pharmacy, University of Genoa, Genoa, Italy; bDepartment of Biomedical Sciences, University of Cagliari, Cittadella Universitaria,
Monserrato, CA, Italy
ABSTRACT
Respiratory syncytial virus (RSV) has been identified as a main cause of hospitalisation in infants and chil-
dren. To date, the current therapeutic arsenal is limited to ribavirin and palivizumab with variable efficacy.
In this work, starting from a number of in-house series of previously described anti-RSV agents based on
the benzimidazole scaffold, with the aim at gaining a better understanding of the related chemical fea-
tures involved in potency and safety profiles, we applied a computational study including two focussed
comparative molecular fields analysis (CoMFA) and comparative molecular similarity indices analysis
(CoMSIA). The results allowed us to derive useful suggestions for the design of derivatives and also to set
up statistical models predicting the potency and selectivity index (SI¼CC50/EC50) of any new analogue
prior to synthesis. Accordingly, here, we discuss preliminary results obtained through the applied exhaust-
ive QSAR analyses, leading to design and synthesise more effective anti-RSV agents.
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Introduction
Respiratory syncytial virus (RSV) is the aetiological agent of serious
and widespread respiratory tract infections that represent the
major cause of hospitalisation of infants and children. The virus is
highly contagious and frequent re-infections may cause morbidity
in elderly people affected by chronic illnesses and in immuno-
compromised individuals. Epidemiologic studies proved RSV as a
ubiquitous contributor to pulmonary exacerbation, particularly in
cystic fibrosis (CF) patients, causing severe clinical symptoms and
promoting comorbidities with bacterial pathogens1.
Despite the huge economic impact and the medical needs asso-
ciated with severe RSV infection, therapy is restricted to ribavirin,
whose effectiveness, however, is highly questionable2. Humanised
monoclonal antibody palivizumab (SynagisVR ) is used for the preven-
tion in high-risk infants, with partial efficacy in reducing RSV hospi-
talisation rates3. Insufficient clinical observation exist to concretely
support whether this drug is cost-effective and safe4,5. Thus, there is
a clear need for new drugs to prevent and treat RSV infection.
Member of Paramyxoviridae family, RSV has a negative-
stranded RNA genome that encodes 11 viral proteins6. The main
antigenic determinants, F (fusion) and G (attachment) glycopro-
teins, are expressed on the virion surface and play a key role in
viral entry into host cells; therefore, they represent interesting tar-
gets of small molecule inhibitors.
Case in point as a future RSV therapeutic is the orally adminis-
tered GS-58067 that was found as a potent inhibitor of a broad
range of RSV clinical isolates by blocking the virus–cell fusion pro-
cess8. GS-5806 needs to be improved for its low efficacy against
the emergent mutant strains, an issue that elicits concern for effi-
cacy of the current antiviral therapies, in general9.
Benzimidazole and its derivatives are important bioactive mole-
cules class in drugs and pharmaceuticals fields10: they exhibit sig-
nificant activity against several viruses and are also endowed with
antimicrobial, anti-inflammatory, antitumour, antiparasitic, antipro-
tozoal properties.
The activity against RSV is peculiar for several benzimidazole-
based chemotypes11, which were demonstrated to target viral rep-
lication machinery by blocking fusion and entry processes12,13.
Continue efforts are devoted to design new RSV inhibitors, by dec-
orating the benzimidazole core structure, from which promising
leads reached clinical trials14. The benzimidazole derivative,
TMC353121, has been shown to inhibit the viral fusion process in
an African green monkeys model15: administered under continu-
ous intravenous infusion, it achieved a complete inhibition of RSV
entry into host cells in a dose-dependent manner, in contrast to
previously described fusion inhibitors that exhibited only a reduc-
tion in viral load.
Recently, we identified three principle classes of anti-RSV
benzimidazole derivatives, such as 2-benzylbenzimidazoles16,
2-phenylbenzimidazoles17 and [(benzotriazol-1/2-yl)methyl] benzi-
midazoles18; among them, the most active compounds showed
even submicromolar potency associated with a high safety profile
(SI¼CC50/EC50). In fact, the 75% of the compound library dis-
played a SI value from>14.3 up to>3333, comparing favourably
with the drug ribavirin (SI >14.3), used as positive control.
In this work, starting from these previously studied series of
benzimidazole-based anti-RSV agents16–18 including 156
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compounds (Figure 1), aiming to gain a better understanding of
the related chemical features involved in potency and safety pro-
files, we applied a computational study including exhaustive quan-
titative structure–activity relationship (3D-QSAR) analyses. Indeed,
the ligand-based approach represents a useful tool guiding for
rational drug design, as shown in the literature19–21.
In detail, we developed two comparative molecular fields ana-
lysis (CoMFA) and comparative molecular similarity indices analysis
(CoMSIA). The first one was performed around the ligands potency
values (pEC50), the second one using the pCC50 parameter (cyto-
toxicity) against human MT-4 cell line. The results allowed us to
derive useful suggestions for the design of new derivatives and
also to set up statistical models predicting the potency and select-
ivity index (SI¼CC50/EC50) of any new analogue prior to synthesis.
Basing on CoMFA and CoMSIA analyses, we deemed interesting
to design and synthesise two new compounds (157, 158), that
bear in position 1 of the (benzotriazol-1-yl)methyl]benzimidazole
scaffold the 2-(N,N-dimethylamino)ethyl or homo-lupinyl chains,
which were previously found as the best suited substitutions,
responsible for a high potency profile. These chemical features
have been now associated with the new investigated apolar CH3
group in position 5 of the benzimidazole ring, with the aim at
improving the activity and even more at reducing the cytotoxicity.
Compound were evaluated against RSV in Vero-76 cell cultures in
order to validate the computational analyses results.
Methods
Data set
All the compounds here evaluated were built in silico and energy
minimised within MOE using MMFF94 force field22. Therefore, all
the compounds were also parameterised by means of the
Gasteiger–H€uckel method. All calculations were carried out using a
PC running the Windows XP operating system.
3D-QSAR analyses
The benzimidazoles 1–156 have been aligned and submitted to
3D-QSAR studies through CoMFA and CoMSIA analyses, by means
of Sybyl-X1.023.
Model A and model B CoMFA and CoMSIA analyses were per-
formed to analyse the impact played by steric, electrostatic,
hydrophobic, H-bond acceptor and H-bond donor features around
the potency as anti-RSV agents and the cytotoxicity trend of these
series of benzimidazoles.
Training set and test set
Starting from all compounds, a number of benzimidazoles
were grouped into a training set, for model generation, and a
test set, for model validation, containing: (i) 50 and 11
compounds for model A; (ii) 123 and 32 derivatives for model B,
respectively. In any model, the molecules selected for the training
and the test set pools were chosen manually, based on represen-
tative criteria of the overall biological activity trend and structural
variations.
For model A and model B analyses, the RSV EC50 values and
the human MT-4 cell line CC50 ones have been transformed into
pEC50 and pCC50 values, respectively, and then used as response
variables.
CoMFA and CoMSIA models and statistical evaluation
CoMFA24 and CoMSIA25 methods are widely used 3D-QSAR techni-
ques being useful to relate any variation of an experimentally
determined parameter (dependent variables), related to a set of
molecules, with respect to specific descriptors which are consid-
ered as independent variables. In particular, the steric and electro-
static fields and especially the hydrophobic, H-bond donor,
H-bond acceptor ones were calculated by CoMFA and CoMSIA
analysis, respectively. Starting from a proper molecule alignment
within a 3D cubic lattice (with a 2 Å grid spacing), any descriptor
was calculated, using the standard Tripos force field method.
Successively, the reliability of the derived models can be evaluated
using specific statistical tools, such as partial least square (PLS)
analysis and cross-validation methods.
Finally, the predictive ability about those compounds included
in the test set (r2pred) was also calculated, by means of the follow-
ing equation:
r2pred ¼ SD PRESSð Þ=SD
being SD and PRESS the sum of the squared deviations between
the biological activities of the test set molecules and the mean
activity of the training set compounds, and the squared deviation
between the observed and the predicted activities of the test set
compounds, respectively.
Any further detail concerning the (standard) CoMFA and
CoMSIA procedures and the statistical and predictive evaluation
we applied, were previously elucidated in a consistent number of
our works26–29.
Chemistry
General synthetic methods
Melting points were taken in open glass capillaries on a B€uchi
apparatus and were uncorrected. Elemental analyses were per-
formed on a Carlo Erba EA-1110 CHNS-O instrument in the
Microanalysis Laboratory of the Department of Pharmaceutical
Sciences of Genoa University. The analytical results are within
±0.4% of calculated values. 1H NMR and 13C NMR spectra
(reported as supplemental material S1–S2) were recorded in CDCl3
or DMSO-d6 on Varian Gemini-200 spectrometer; d in ppm rel. to
Me4Si as internal standard. J in Hz. Q¼quinolizidine ring. Results
of elemental analyses, thin-layer chromatography (TLC) and
114-156
25-113
1-24
non-Ar/benzyl
substituents
1-156
Ar substituentsR
R
R1
N
N
R1
N
NR3
R4
R2
R1
N
N
R1
N
N
N
N
N
R3
Figure 1. General structures of benzimidazole-based anti-RSV agents
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nuclear magnetic resonance (NMR) spectra indicated that the pur-
ity of all compounds was 95%.
Chemicals, solvents and commercially available intermediates
were purchased from Aldrich (Milan). The non-commercially avail-
able intermediates were prepared according to the literature, or as
follows, when not previously known.
2-[(1H-1,2,3-benzotriazol-1-yl)methyl]-1-[2-(N,N-dimethylamino)
ethyl]-5-methylbenzimidazole (157) and 2-[(1H-1,2,3-benzotriazol-
1-yl)methyl]-1-[(1S,9aR)-(octahydro-2H-quinolizin-1-yl)ethyl]-5-
methylbenzimidazole (158) General synthetic method. A mixture of
the proper N-substituted 1,2-phenylenediamine (3.6mmol) and
(1H-1,2,3-benzotriazol-1-yl)acetic acid (1.28 g, 7.2mmol) was heated
at 180 C under N2 for 90min with manual stirring. After cooling,
1N HCl (20mL) was added, filtering and washing with H2O an
amount of unreacted acid. The aqueous solutions were basified
with a solution of 6N NaOH and extracted with Et2O. After drying
(Na2SO4) the solvent was evaporated, leaving a spongy residue
that was cromatographed or crystallised with dry Et2O.
157. Yield: 66%. CC(Al2O3/Et2O). M.p. 125–126 C.
1H-NMR
(200MHz, CDCl3): 2.29 (s, 6H, N(CH3)2); 2.38 (t, J¼ 7.0, 2H,
CH2CH2N(CH3)2); 2.51 (s, 3H, CH3Ar); 4.31 (t, J¼ 7.2, 2H,
CH2CH2N(CH3)2); 6.27 (s, 2H, CH2-benzotriazole); 7.12–7.25 (m, 2
arom. H); 7.33–7.48 (m, 2 arom. H); 7.60–7.67 (m, 1 arom. H);
7.76–7.84 (m, 1 arom. H); 8.03–8.10 (m, 1 arom. H). 13C NMR
(50MHz, CDCl3): 145.72, 145.20, 141.51, 132.33, 131.98, 131.43,
126.96, 124.22, 123.36, 118.99, 118.72, 109.62, 108.40, 56.81, 45.02,
44.55, 41.22, 20.45. Anal. calc. for C19H22N6: C 68.24, H 6.63, N
25.13; Found: C 68.05, H 6.55, N 25.17.
158. Yield: 40%. M.p. 171–172 C (Et2O).
1H-NMR (200MHz,
CDCl3): 1.00–2.05 (m, 16H of CH2-Q); 2.51 (s, CH3); 2.68–2.88 (m,
2H, Ha near N of Q); 4.07–4.31 (m, 2H of CH2-CH2-Q); 6.09–6.35 (AB
syst., 2H, CH2-benzotriazole); 7.08–7.46 (m, 4 arom. H); 7.60–7.82
(m, 2 arom. H); 8.04 (d, J¼ 9.0, 1 arom. H). 13C NMR (50MHz,
CDCl3): 145.22, 144.74, 141.46, 132.35, 131.90, 131.36, 127.05,
124.24, 123.38, 118.91, 118.61, 109.68, 108.59, 45.24, 42.25, 34.95,
23.03, 20.47, 19.81. Anal. calc. for C26H32N6: C 72.87, H 7.53, N
19.61; Found: C 72.92, H 7.64, N 19.29.
Intermediates. N-substituted 1,2-phenylendiamines General syn-
thetic method. To a stirred solution of the above nitroderivative
(1.3mmol) in EtOH (7mL), a solution of SnCl2.2H2O (3.9mmol,
0.88 g) in conc. HCl (10mL) was slowly added. The mixture was
refluxed for 6 h and then concentrated in vacuo. The residue was
taken up in H2O, alkalinised with a solution of 6N NaOH and then
extracted with Et2O. The organic layer was dried (Na2SO4), filtered
and then evaporated, affording a yellow oil. A small amount was
converted into dihydrochloride salt with a 1N ethanolic solution of
HCl for performing elemental analysis.
2-Amino-N-[2-(N’,N’-dimethylamino)ethyl]-4-methylbenzeneamine
Yield: 88%. 1H-NMR (200MHz, CDCl3): 2.26 (s, 6H, N(CH3)2); 2.28 (s,
ArCH3); 2.60 (t, J¼ 7.2, 2H, CH2CH2N(CH3)2); 3.16 (t, J¼ 7.2, 2H,
CH2CH2N(CH3)2); 3.30–3.60 (br s, 3H, NH2 and NH, collapse with
D2O); 6.55–6.70 (m, 3 arom. H). Dihydrochloride: M.p. 186–189 C
(EtOH). Anal. calc. for C11H19N3þ2HCl: C 49.63, H 7.95, N 15.78;
Found: C 49.66, H 7.85, N 15.60.
2-Amino-N-[2-(1S,9aR)-(octahydro-2H-quinolizin-1-yl)ethyl]-4-meth-
ylbenzeneamine Yield: 82%. 1H-NMR (200MHz, CDCl3): 1.20–2.03
(m, 16 H of Q); 2.21 (s, 3 H, CH3Ar); 2.76–2.85 (m, 2 H, Ha near N of
Q); 2.95–3.04 (m, 1 H of CH2NH); 3.07–3.18 (m, 1 H of CH2NH); 3.31
(br. s, 3 H, NH and NH2, collapse with D2O); 6.53–6.62 (m, 3 arom.
H). Dihydrochloride: M.p. 106–109 C (with swelling). Anal. calc. for
C18H29N3þ2HCl: C 59.99, H 8.68, N 11.66; Found: C 59.87, H 8.76,
N 11.62.
N-[2-(1S,9aR)-(octahydro-2H-quinolizin-1-yl)ethyl]-4-methyl-2-nitro-
benzeneamine A solution of homo-lupinylamine (5mmol) and
4-chloro-3-nitrotoluene (5mmol) in DMF (3mL) was heated in a
pressure tube at 120 C with stirring for 9 h. At room temperature,
H2O was added and the mixture alkalinised with a solution of 6N
NaOH and extracted with Et2O. The organic phase was extracted
with diluted HCl; the acid solution was alkalised and extracted
with Et2O. After evaporation, the oily residue was purified by
CC(SiO2/Et2Oþ 2%MeOH). A small amount was converted into
monohydrochloride salt (M.p. 176–179 C) with 1N ethanolic solu-
tion of HCl for performing elemental analysis.
Yield: 40%. 1H-NMR (200MHz, CDCl3): 1.18–2.06 (m, 16 of Q);
2.25 (s, 3H, CH3Ar); 2.77–2.84 (m, 2H, Ha near N of Q); 3.17–3.25 (m,
1H, CH2NH); 3.28–3.40 (m, 1H, CH2NH); 6.78 (d, J¼ 9.0, 1 arom. H);
7.24 (dd, J¼ 8.6, 1.2, 1 arom. H); 7.84 (br. s, 1H, NH, collapses with
D2O); 8.00 (d, J¼ 9.2, 1 arom. H). Anal. calc. for C18H27N3O2þHCl: C
61.09, H 7.97, N 11.87; Found: C 61.03, H 8.23, N 11.84.
Biological assays
Cells and viruses
Cell lines and RSV were purchased from American Type Culture
Collection (ATCC). The absence of mycoplasma contamination was
checked periodically by the Hoechst staining method. Cell line
supporting the multiplication of RSV was the Monkey kidney (Vero
76) [ATCC CRL 1587 Cercopithecus Aethiops], while CD4þhuman
T cells containing an integrated HTLV-1 genome (MT-4) was used
as human cellular model. Human respiratory syncytial virus (RSV)
[strain A2 (ATCC VR-1302)].
Cytotoxicity assays
a. Exponentially growing MT-4 cells were seeded at an initial
density of 1 105 cells/mL in 96-well plates in RPMI-1640
medium supplemented with 10% foetal bovine serum (FBS),
100 units/mL penicillin G and 100 mg/mL streptomycin. Cell
cultures were then incubated at 37 C in a humidified, 5%
CO2 atmosphere in the absence or presence of serial dilutions
of test compounds. Cell viability was determined after 96 h at
37 C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazo-
lium bromide (MTT) method30.
b. Vero-76 cells were seeded at an initial density of 4 105 cells/
mL in 24-well plates, in culture medium (Dulbecco’s modified
Eagle medium (D-MEM) with L-glutamine, supplemented with
foetal bovine serum (FBS), 0.025 g/L kanamycin). Cell cultures
were then incubated at 37 C in a humidified, 5% CO2 atmos-
phere in the absence or presence of serial dilutions of test
compounds. Cell viability was determined after 48–96 h at
37 C by the crystal violet staining method.
c. The results are expressed as CC50, which is the concentration
of compound necessary to inhibit cell growth by 50%. Each
CC50 value is the mean and standard deviation of at least
three separate experiments performed in duplicate.
Antiviral assays
Antiviral activity against RSV was determined by plaque reduction
assays in infected cell monolayers. To this end, Vero 76-cells were
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seeded in 24-well plates at a density of 2 105 cells/well and
were allowed to form confluent monolayers by incubating over-
night in growth medium (Dulbecco’s modified Eagle medium
(D-MEM) with L-glutamine and 4500mg/L D-glucose and 0.025 g/L
kanamycin, supplemented with 10% FBS) at 37 C in a humidified
CO2 (5%) atmosphere. Then, monolayers were infected for 2 h with
250 mL of proper viral dilutions to give 50 to 100 PFU/well.
Following removal of unadsorbed virus, 500 mL of maintenance
medium [D-MEM with L-glutamine and 4500mg/L D-glucose, sup-
plemented with 1% inactivated FBS] containing 0.75% methylcellu-
lose, without or with serial dilutions of test compounds, were
added. Cultures were incubated at 37 C for 5 days and then fixed
with PBS containing 50% ethanol and 0.8% crystal violet, washed
and air-dried. Plaques were then counted.
Linear regression analysis
The extent of cell growth/viability and viral multiplication, at each
drug concentration tested, were expressed as percentage of
untreated controls. Concentrations resulting in 50% inhibition
(CC50 or EC50) were determined by linear regression analysis.
Results
Chemistry
Preparations of compounds 157 and 158 were accomplished by
the general synthetic steps in Scheme 1.
While the N-[2-(N0,N0-dimethylamino)ethyl]-4-methyl-2-nitroben-
zeneamine was obtained according to the literature31, the
N-(homo-lupinyl)-4-methyl-2-nitrobenzeneamine was synthesised
by reacting the 1-chloro-4-methyl-2-nitrobenzene with homo-lupi-
nylamine (2-((1S,9aR)-octahydro-2H-quinolizin-1-yl)ethanamine)32 at
120 C for 9 h. Then, the two nitrobenzene amines were reduced
with SnCl22H2O in concentrated HCl to give the corresponding
1,2-phenylendiamines that were heated to fusion at 180 C for
90min with 1H-1,2,3-benzotriazol-1-ylacetic acid33, providing the
title compounds.
Biological activity
The two newly synthesised benzimidazole derivatives were
assayed for in vitro antiviral activity against the respiratory syncyt-
ial virus (RSV). Cytotoxicity was evaluated in parallel with the anti-
viral activity against the primate Vero76 and human MT-4 cell
lines. As reference inhibitors were used ribavirin (pEC50¼5.15MT-4
pCC50¼4.51), NM299 (6-azauridine; pEC50¼5.92MT-4 pCC50¼5.70)
and M5255 (mycophenolic acid; pEC50¼6.22MT-4 pCC50¼6.70).
3D-QSAR analyses
Starting from the in-house compounds 1–156 (Table 1), CoMFA
and CoMSIA analyses here reported were used to explore, through
quantitative methods, the main features responsible for the anti-
RSV activity (model A) of benzimidazole-based derivatives and also
for the related cytotoxicity profile (model B).
For both models, calculations were developed using CoMFA
steric and electrostatic fields, and CoMSIA steric, electrostatic,
hydrophobic, H-bond acceptor and H-bond donor parameters, as
independent variables. On the other hand, the RSV pEC50 and the
MT-4 pCC50 were employed as dependent variables for model A
and B, respectively (experimental section).
Concerning model A, CoMFA and CoMSIA analyses were per-
formed choosing among compounds 1–156 a training set pool
molecules (2, 9, 11, 12, 14, 15, 21, 23, 25, 27, 29–31, 44, 100,
102, 114–120, 122–129, 131–134, 136, 138–141, 143, 145, 146,
149–153, 155, 156) for model generation and a test set one (20,
24, 103, 112, 121, 135, 137, 142, 144, 147, 148), for model valid-
ation. Model B CoMFA and CoMSIA analyses were performed
including compounds 2–4, 6–20, 22–29, 31–33, 35, 37–39,
41–46, 49–51, 53–57, 59–65, 67–72, 74, 75, 77–81, 84, 86,
88–91, 93–95, 97, 98, 100–104, 106–108, 110, 111, 113–115,
118–121, 123, 125–129, 131–137, 139–149, 151–154, 156 into
the training set, while compounds 1, 5, 19, 21, 30, 34, 36, 40, 47,
48, 52, 58, 66, 73, 76, 82, 83, 85, 87, 92, 96, 99, 105, 109, 112,
116, 117, 124, 130, 138, 150, 155 were included in the test set.
All statistical parameters supporting the two series of 3D-QSAR
analyses are reported in Table 2, while final models A and B
experimental and predicted pEC50 (pCC50) values are listed in
Tables 3–6. Any detail is described as follows.
The final model A CoMFA was generated by employing non-
cross-validated PLS analysis with the optimum number of compo-
nents (ONC¼ 5) to give a non-cross validated r2 (r2ncv)¼ 0.92, a
test set r2 (r2pred)¼ 0.88, standard error of estimate (SEE)¼ 0.279,
steric contribution¼ 0.574 and electrostatic contribution¼ 0.426.
The related CoMSIA analysis was derived using a statistical PLS
analysis leading to the following results: ONC¼ 5, a non-cross vali-
dated r2 (r2ncv)¼ 0.89, a test set r2 (r2pred)¼ 0.88, standard error of
estimate (SEE)¼ 0.305, steric contribution¼ 0.131, electrostatic
contribution¼ 0.203, hydrophobic contribution¼ 0.223, H-bond
acceptor¼ 0.208 and H-bond donor¼ 0.235.
An overall overview of the predictive ability of model A study
can be obtained from graphical distributions of the predicted
H3C NO2
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R
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Scheme 1. Reagents and conditions: (a) 120 C, 9 h; (b) SnCl2 . 2H2O, conc. HCl, EtOH, 6 h at reflux; (c) 180 , N2, 90min.
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Table 1. Chemical structure of benzimidazoles 1–156 and the related anti-RSV potency and cytotoxicity profiles (evaluated against MT-4 and VERO-76 cell lines)
R2
R1
R4
R3
N
N
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
1
N
H
–CH3 –CF3 –H <4.00 4.00 4.00
2
N
H
–CF3 –CF3 –H 4.66 4.27 4.00
3 -H –H –H <4.00 4.00 4.00
4
N
H
–CF3 –H <4.00 4.96 4.00
5 –H
NH2
–H –H <4.00 4.00 4.00
6 –H
Cl
–CF3 –H < 4.00 4.00 4.15
7 –H
OCH3
–CF3 –H <4.00 4.16 4.04
8 –H
NH2
–CF3 –H <4.00 4.00 4.00
9 –C4H9(n)
Cl
Cl
–CF3 –H 5.05 4.00 4.00
10 –CH2CH2OCH3
Cl
Cl
–CF3 –H <4.00 4.00 4.00
11 –H
OCH3
–Cl –Cl 5.30 4.54 4.00
12 –H
NH2
–Cl –Cl 4.70 4.15 4.10
13 –(CH2)2N(C2H5)2
Cl
–H –H <4.00 4.38 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
14 –(CH2)2N(C2H5)2
Br
–H –H 4.12 4.31 4.00
15 –(CH2)2N(C2H5)2
I
–H –H 4.40 4.60 4.00
16 –(CH2)2N(CH3)2
Cl
Cl
–CF3 –H <4.00 4.00 4.00
17 –(CH2)3N(C2H5)2
Cl
Cl
–CF3 –H <4.00 4.40 4.00
18
N
H
–CF3 –H <4.00 4.00 4.03
19
N
H
–CF3 –H <4.00 4.00 4.00
20
N
H
Cl
–CF3 –H 4.82 5.22 4.00
21
N
H
Br
–CF3 –H 4.60 4.89 4.00
22
N
H
Cl
–Cl –Cl <4.00 4.77 4.00
23
N
H
Cl
Cl
–Cl –Cl 4.92 5.05 4.00
24
N
H
Br
–Cl –Cl 5.05 4.92 4.00
25 –H
NO2
–H –H 4.40 4.22 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
26 –H
NO2
NO2
–H –H <4.00 5.15 4.00
27 –H
OH
–CF3 –H 4.70 4.77 4.00
28 –H
OCH3
–CF3 –H <4.82 5.70 4.82
29 –H
OCH3
–CF3 –H 5.15 4.72 4.00
30 –H
OCH3
OCH3
–CF3 –H 4.00 4.00 4.00
31 –H
OCH3
OCH3
–CF3 –H 5.00 4.72 4.00
32 –H
OCH3
OCH3
OCH3
–CF3 –H <4.15 4.03 4.15
33 –H
OCH3
OCH3
OCH3
–CF3 –H <4.54 5.40 4.54
34 –H
NO2
OCH3
–CF3 –H <4.07 4.70 4.07
35 –H
NH2
OCH3
–CF3 –H <4.30 5.30 4.30
36 –H
NO2
–CF3 –H <4.35 5.22 4.35
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
37 –H
NO2
NO2
–CF3 –H <4.60 5.05 4.60
38 –H
F
–CF3 –H <4.22 4.66 4.22
39 –H
F
F
–CF3 –H <4.60 4.00 4.60
40 –H
OCH3
OCH3
–NO2 –H <4.00 4.00 4.00
41 –H
OCH3
OCH3
OCH3
–NO2 –H <4.00 4.00 4.00
42 –H
OCH3
OCH3
–COCH3 –H <.00 4.00 4.00
43 –H
OCH3
OCH3
OCH3
–COCH3 –H <4.00 4.00 4.00
44 –H
OH
–Cl –Cl 5.15 4.92 4.74
45 –H
OCH3
–Cl –Cl <4.52 6.00 4.52
46 –H
NO2
OCH3
–Cl –Cl <4.10 5.70 4.10
47 –H
NH2
OCH3
–Cl –Cl <4.12 5.52 4.12
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
48 –H
NO2
–Cl –Cl <4.00 4.77 4.00
49 –H
F
F
–Cl –Cl <4.00 4.77 4.00
50 –H
NH2
–H –H n.d 4.00 4.00
51 –H
NHCOCH3
–H –H n.d 4.00 4.00
52 –H
NHCOC2H5
–H –H n.d 4.46 4.00
53 –H
N
O
N
H
–H –H n.d 4.40 4.00
54 –H
N
O
N
H
–H –H n.d 4.51 4.00
55 –H
O
N
O
N
H
–H –H n.d 4.00 4.00
56 –H
H
N
–H –H n.d 4.74 4.10
57 –H
NH2
–CF3 –H n.d 4.21 4.00
58 –H
NHCOCH3
–CF3 –H n.d 4.72 4.30
59 –H
NHCOC2H5
–CF3 –H n.d 4.00 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
60 –H
NHCOC2CI
–CF3 –H n.d 5.30 4.46
61 –H
O
N
H
N
H
–CF3 –H n.d 4.82 4.35
62 –H
NHCOCH2N(C2H5)2
–CF3 –H n.d 5.10 4.62
63 –H
N
O
N
H
–CF3 –H n.d 4.74 4.00
64 –H
N
O
N
H
–CF3 –H n.d 5.22 4.51
65 –H
O
N
O
N
H
–CF3 –H n.d 4.00 4.00
66 –H
O
N
S
N
H
–CF3 –H n.d 5.00 4.00
67 –H
Ph
NO
N
N
H
–CF3 –H n.d 6.05 4.00
68 –H
H
N
–CF3 –H n.d 5.40 4.40
69 –H
NHCO(CH2)2COOH
–CF3 –H n.d 4.00 4.00
70 –H
NH2
–NO2 –H n.d 4.00 4.00
71 –H
NHCOCH3
–NO2 –H n.d 4.00 4.00
72 –H
NH2
–Cl –Cl n.d 4.77 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
73 –H
NHCOCH3
–Cl –Cl n.d 4.00 4.00
74 –H
N
O
N
H
–Cl –Cl n.d 5.10 4.00
75 –H
N
O
N
H
–Cl –Cl n.d 4.27 4.00
76 –H
O
N
O
N
H
–Cl –Cl n.d 4.74 4.00
77 –H
O
N
S
N
H
–Cl –Cl n.d 4.00 4.00
78 –H
N
CH3O
N
N
H
–Cl –Cl n.d 4.96 4.00
79 –CH3
NH2
–CF3 –H n.d 4.70 4.00
80 –CH3
NHCOCH3
–CF3 –H n.d 4.82 4.00
81 –CH3
NHCOC2H5
–CF3 –H n.d 5.10 4.00
82 –CH3
NHCOCH2N(C2H5)2
–CF3 –H n.d 5.04 4.05
83 –CH3
N
O
N
H
–CF3 –H n.d 4.80 4.00
84 –CH3
N
O
N
H
–CF3 –H n.d 5.05 4.00
85 –CH3
O
N
O
N
H
–CF3 –H n.d 4.00 4.00
86 –CH3
O
N
S
N
H
–CF3 –H n.d 5.00 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
87 –CH3
N
CH3O
N
N
H
–CF3 –H n.d 4.66 4.00
88 –CH3
Ph
NO
N
N
H
–CF3 –H n.d 5.82 4.52
89
NH2
–CF3 –H n.d 4.36 4.00
90
NHCOCH3
–CF3 –H n.d 4.62 4.52
91
NHCOC2H5
–CF3 –H n.d 4.77 4.00
92
NH2
–CF3 –H n.d 4.72 4.22
93
NHCOCH3
–CF3 –H n.d 4.55 4.00
94
NHCOC2H5
–CF3 –H n.d 4.07 4.00
95
NHCOCH2CI
–CF3 –H n.d 6.52 4.00
96
Ph
NO
N
N
H
–CF3 –H n.d 4.00 4.00
97 –CH3
NO2
–CF3 –H < 4.00 4.00 4.00
98
NO2
–CF3 –H <4.00 4.31 4.00
99
N
H
–H –H <4.00 4.48 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
100
N
H
–H –H 5.15 4.38 4.00
101
N
H
– H –H <4.00 4.00 4.00
102
N
H
F
– H –CH3 4.20 4.00 4.00
103
N
H
– H –Cl 4.35 4.25 4.05
104
N
H
OCH3
– Cl –H <4.00 4.00 4.00
105
H
N
–H –Cl <4.00 4.00 4.00
106
N
H
Cl
–CF3 –H <4.62 4.62 4.62
107
N
H
F
F
–CF3 –H <4.00 4.24 4.00
108
N
H
OH
–CF3 –H <4.11 4.68 4.11
109
N
H
OCH3
–Cl –Cl <.12 4.60 4.12
110
N
H
OCH3
–Cl –Cl <4.00 4.38 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
111 –C4H9(n)
OCH3
–CF3 –H <4.10 4.00 4.10
112 –CH2-C6H5 –H –H 4.60 4.33 4.06
113 –H
N
H
–H –H <4.00 4.77 4.00
114 –(CH2)2N(CH3)2
N
N
N
–H –H 6.15 4.00 4.00
115 –(CH2)2N(C2H5)2
N
N
N
–H –H 5.64 4.00 4.00
116 –(CH2)3N(C2H5)2
N
N
N
–H –H 6.15 4.00 4.00
117
N
H
N
N
N
–H –H 6.15 4.00 4.00
118
N
H
N
N
N
–H –H 6.52 4.04 4.00
119
H
N
N
N
N
–H –H 6.82 4.19 4.00
120 –(CH2)2N(CH3)2
N
N
N
–Cl –H 7.52 4.00 4.00
121 –(CH2)2N(C2H5)2
N
N
N
–Cl –H 6.15 4.00 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
122 –(CH2)3N(CH3)2
N
N
N
–Cl –H 7.22 4.00 4.00
123 –(CH2)3N(C2H5)2
N
N
N
–Cl –H 7.00 4.30 4.00
124
N
H
N
N
N
–Cl –H 6.05 4.43 4.22
125
N
H
N
N
N
–Cl –H 7.30 4.44 4.06
126
H
N
N
N
N
–Cl –H 7.70 4.80 4.35
127 –(CH2)2N(CH3)2
N
N
N
–CF3 –H 5.00 4.00 4.00
128 –(CH2)2N(C2H5)2
N
N
N
–CF3 –H 5.15 4.00 4.00
129 –(CH2)3N(C2H5)2
N
N
N
–CF3 –H 5.72 4.30 4.00
130
N
H
N
N
N
–CF3 –H <4.44 4.04 4.44
131 –(CH2)2N(CH3)2
N
N
N
–NO2 –H 5.05 4.00 4.00
132 –(CH2)2N(C2H5)2
N
N
N
–NO2 –H 4.96 4.00 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
133
N
H
N
N
N
–NO2 –H 4.64 4.41 4.08
134 –(CH2)2N(CH3)2
N
N
N
–COCH3 –H 5.74 4.00 4.00
135 –(CH2)2N(C2H5)2
N
N
N
–COCH3 –H 5.15 4.00 4.00
136 –(CH2)3N(C2H5)2
N
N
N
–COCH3 –H 5.92 4.10 4.00
137
N
H
N
H
–COCH3 –H 5.60 4.11 4.10
138 –(CH2)3N(C2H5)2
N
N
N
–H –H 5.82 4.00 4.00
139
N
H N
N
N
–H –H 6.15 4.00 4.00
140
N
H N
N
N
–H –H 5.92 4.03 4.00
141
H
N
N
N
N
–H –H 7.00 4.15 4.00
142 –(CH2)2N(CH3)2
N
N
N
–Cl –H 6.52 4.00 4.00
143 –(CH2)2N(C2H5)2
N
N
N
–Cl –H 6.40 4.10 4.00
144 –(CH2)3N(CH3)2
N
N
N
–Cl –H 5.82 4.00 4.00
(continued)
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Table 1. Continued
Comp. R1 R2 R3 R4 RSV pEC50 MT-4 pCC50 VERO-76 pCC50
145 –(CH2)3N(C2H5)2
N
N
N
–Cl –H 6.22 4.15 4.00
146
N
H N
N
N
–Cl –H 6.00 4.30 4.30
147
N
H N
N
N
–Cl –H 6.22 4.30 4.12
148
H
N
N
N
N
–Cl –H 7.52 4.52 4.00
149 –(CH2)2N(CH3)2
N
N
N
–CF3 –H 5.60 4.00 4.00
150 –(CH2)2N(C2H5)2
N
N
N
–CF3 –H 5.70 4.05 4.00
151
N
H N
N
N
–CF3 –H 4.96 4.40 4.10
152 –(CH2)2N(CH3)2
N
N
N
–NO2 –H < 4.00 4.22 4.00
153 –(CH2)2N(C2H5)2
N
N
N
–NO2 –H <4.00 4.00 4.00
154
N
H N
N
N
–NO2 –H <4.10 4.35 4.10
155 –(CH2)2N(C2H5)2
N
N
N
–COCH3 –H 4.70 4.00 4.00
156
N
H N
N
N
–COCH3 –H 5.60 4.39 4.10
All the listed compounds have been previously described16–18.
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pEC50 values of the training set and test compounds, as shown in
Supplemental materials S3–S4.
The selected CoMFA model B was generated by employing non-
cross-validated PLS analysis with the optimum number of compo-
nents (ONC¼ 8) to give a non-cross validated r2 (r2ncv)¼ 0.91, a
test set r2 (r2pred)¼ 0.63, standard error of estimate (SEE)¼ 0.161,
steric contribution¼ 0.597 and electrostatic contribution¼ 0.403.
The CoMSIA model B was obtained with the following statistical
results: ONC¼ 8, a non-cross validated r2 (r2ncv)¼ 0.87, a test set
r2 (r2pred)¼ 0.56, standard error of estimate (SEE)¼ 0.196, steric con-
tribution¼ 0.151, electrostatic contribution¼ 0.196, hydrophobic
contribution¼ 0.260, H-bond acceptor¼ 0.156 and H-bond
donor¼ 0.238.
The derived distributions of the predicted pCC50 values of
the training set and test compounds are as Supplemental material
S5–S6.
The CoMFA and CoMSIA model A and B reliability thus gener-
ated was supported also by bootstrapping results (Table 2).
Discussion
CoMFA and CoMSIA contour maps
In order to deeply discuss the contribution of any feature dis-
played within the series of benzimidazoles here investigated with
respect to their potency as anti-RSV agents, and also to their cyto-
toxicity profile, the description of the related 3D-QSAR models (A
and B, respectively) was organised in two sections separately.
According to the CoMFA steric map descriptors, green polyhe-
dra represent those areas that should be decorated with bulky
Table 2. Summary of CoMFA and CoMSIA analyses calculated as model A and B.
Model A Model B
CoMFA CoMSIA CoMFA CoMSIA
No. compounds 50 50 123 123
Optimal number of components (ONC) 5 5 8 8
Leave one out r2 (r2loo) 0.653 0.725 0.612 0.641
Cross validated r2 (r2cv) 0.703 0.710 0.726 0.712
Std. error of estimate (SEE) 0.279 0.305 0.161 0.196
Non-cross validated r2 (r2ncv) 0.92 0.89 0.91 0.87
F value 90.457 57.341 128.631 82.855
Steric contribution 0.574 0.131 0.597 0.151
Electrostatic contribution 0.426 0.203 0.403 0.196
H-bond acceptor contribution – 0.208 – 0.156
H-bond donor contribution – 0.235 – 0.238
Hydrophobicity contribution – 0.2223 – 0.260
Bootstrap r2 (r2boot) 0.980 0.943 0.981 0.975
Standard error of estimate r2boot (SEE r
2
boot) 0.210 0.232 0.267 0.269
Test set r2 (r2pred) 0.88 0.88 0.63 0.56
Table 3. Model A CoMFA and CoMSIA analyses experimental and predicted
pEC50 values of the training set compounds.
CoMFA model CoMSIA model
Compound Exp. pEC50 Pred. pEC50 Residual Pred. pEC50 Residual
2 4.66 4.94 0.28 4.247 0.41
9 5.05 5.28 0.23 5.211 0.16
11 5.30 5.05 0.25 5.375 0.08
12 4.70 4.68 0.02 4.544 0.16
14 4.12 4.17 0.04 4.058 0.06
15 4.40 4.18 0.22 4.049 0.35
21 4.60 4.78 0.18 4.745 0.15
23 4.92 5.05 0.13 5.143 0.22
25 4.40 4.71 0.31 4.422 0.02
27 4.70 4.64 0.06 4.968 0.27
29 5.15 5.09 0.06 4.703 0.45
30 4.00 4.07 0.07 4.12 0.12
31 5.00 5.12 0.12 4.838 0.16
44 5.15 4.85 0.30 5.289 0.14
100 5.15 4.97 0.18 5.154 0.00
102 4.20 3.96 0.24 4.135 0.07
114 6.15 6.56 0.41 6.441 0.29
115 5.64 5.66 0.02 6.116 0.48
116 6.15 6.46 0.31 6.535 0.39
117 6.15 5.87 0.28 6.084 0.07
118 6.52 6.78 0.26 6.532 0.01
119 6.82 7.08 0.26 7.064 0.24
120 7.52 6.98 0.54 6.798 0.72
122 7.22 6.98 0.25 6.798 0.42
123 7.00 6.90 0.10 6.772 0.23
124 6.05 6.26 0.21 6.421 0.37
125 7.30 7.22 0.08 6.923 0.38
126 7.70 7.54 0.16 7.45 0.25
127 5.00 5.32 0.32 5.906 0.91
128 5.15 4.69 0.46 5.562 0.41
129 5.72 5.54 0.18 5.307 0.41
131 5.05 5.07 0.02 5.098 0.05
132 4.96 4.80 0.16 4.798 0.16
133 4.64 4.87 0.23 4.641 0.00
134 5.74 5.67 0.07 5.314 0.43
136 5.92 5.99 0.07 5.756 0.16
138 5.82 5.77 0.05 5.624 0.20
139 6.15 5.68 0.47 5.852 0.30
140 5.92 5.71 0.21 5.909 0.01
141 7.00 7.12 0.12 7.34 0.34
143 6.40 6.56 0.16 6.023 0.38
145 6.22 6.42 0.20 6.017 0.20
146 6.00 6.08 0.08 6.144 0.14
149 5.60 5.02 0.59 5.453 0.15
150 5.70 5.28 0.42 5.356 0.34
151 4.96 5.14 0.18 5.573 0.61
152 4.00 4.73 0.73 4.64 0.64
153 4.00 4.39 0.39 4.502 0.50
155 4.70 5.00 0.30 4.907 0.21
156 5.60 5.52 0.08 5.113 0.49
Table 4. Model A CoMFA and CoMSIA analyses experimental and predicted
pEC50 values of the test set compounds.
CoMFA model CoMSIA model
Compound Exp. pEC50 Pred. pEC50 Residual Pred. pEC50 Residual
20 4.82 4.99 0.17 4.75 0.07
24 5.05 4.91 0.14 5.08 0.03
103 4.35 3.90 0.45 4.04 0.31
112 4.60 4.77 0.17 4.39 0.21
121 6.15 5.87 0.28 6.48 0.32
135 5.15 4.95 0.20 4.98 0.17
137 5.60 5.93 0.33 5.18 0.42
142 6.52 5.97 0.55 5.95 0.57
144 5.82 6.32 0.50 6.29 0.47
147 6.22 6.12 0.10 6.19 0.03
148 7.52 7.68 0.16 7.76 0.24
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groups, while yellow maps highlight those regions related to an
unfavourable or slightly allowed presence of substituents. On the
other hand, the CoMFA electrostatic descriptors are shown as blue
areas around those regions predicted to be beneficial for electro-
positive or electron donor moieties, while red polyhedra occupy
any area recommended for much more electronegative or electron
withdrawing.
Concerning CoMSIA analysis, the hydrophobic map reveals
through yellow and white polyhedra those ligand features pre-
dicted to be favoured for lipophilic and polar groups,
respectively.
The introduction of H-bond acceptor and H-bond donor
moieties results to be encouraged or discouraged by the pres-
ence of magenta and cyan and of red and purple areas,
respectively.
Table 5. Model B CoMFA and CoMSIA analyses experimental and predicted
pCC50 values of the training set compounds.
CoMFA model CoMSIA model
Compound Exp. pCC50 Pred. pCC50 Residual Pred. pCC50 Residual
2 4.27 4.41 0.14 4.56 0.29
3 4.00 3.85 0.15 3.92 0.08
4 4.96 5.13 0.17 4.85 0.12
6 4.00 4.06 0.06 4.12 0.12
7 4.16 4.09 0.07 4.16 0.00
8 4.00 3.90 0.11 3.86 0.14
9 4.00 3.98 0.02 3.96 0.04
10 4.00 3.87 0.13 3.92 0.08
11 4.54 4.37 0.17 4.48 0.06
12 4.15 4.38 0.23 4.17 0.02
13 4.38 4.34 0.04 4.15 0.23
14 4.31 4.38 0.07 4.23 0.08
15 4.60 4.36 0.24 4.37 0.23
16 4.00 3.97 0.03 4.30 0.30
17 4.40 4.29 0.11 4.39 0.01
18 4.00 4.21 0.21 4.07 0.07
20 5.22 4.96 0.26 4.72 0.50
22 4.77 5.03 0.26 5.00 0.23
23 5.05 4.84 0.21 4.92 0.13
24 4.92 5.08 0.16 5.09 0.17
25 4.22 4.29 0.07 3.96 0.27
26 5.15 5.32 0.17 5.02 0.13
27 4.77 4.65 0.12 4.74 0.03
28 5.70 5.59 0.11 5.31 0.39
29 4.72 4.73 0.01 4.53 0.19
31 4.72 4.82 0.10 4.73 0.01
32 4.03 3.86 0.17 4.17 0.14
33 5.40 5.57 0.17 5.12 0.28
35 5.30 5.32 0.02 5.42 0.12
37 5.05 5.10 0.05 4.80 0.25
38 4.66 4.55 0.11 4.58 0.09
39 4.00 4.41 0.41 4.47 0.47
41 4.00 4.06 0.06 4.26 0.26
42 4.00 3.98 0.02 3.97 0.04
43 4.00 4.02 0.01 4.10 0.10
44 4.92 4.79 0.14 5.05 0.13
45 6.00 5.73 0.27 5.61 0.39
46 5.70 5.79 0.09 5.93 0.23
49 4.77 4.61 0.16 4.78 0.01
50 4.09 4.01 0.09 3.99 0.10
51 4.00 3.99 0.01 4.17 0.17
53 4.40 4.49 0.09 4.30 0.10
54 4.51 4.42 0.09 4.31 0.20
55 4.00 4.16 0.16 4.04 0.04
56 4.74 5.04 0.30 4.83 0.09
57 4.21 4.48 0.27 4.37 0.16
59 4.00 4.02 0.02 4.52 0.52
60 5.30 4.93 0.38 4.95 0.35
61 4.82 4.90 0.08 4.78 0.04
62 5.10 5.07 0.03 5.10 0.00
63 4.74 4.85 0.11 4.83 0.09
64 5.22 4.79 0.43 5.21 0.01
65 4.00 4.51 0.51 4.00 0.00
67 5.22 5.20 0.02 5.44 0.22
68 5.40 5.40 0.00 5.20 0.20
69 4.00 4.15 0.15 4.22 0.22
70 4.00 4.17 0.17 4.12 0.12
71 4.00 4.16 0.16 4.29 0.29
72 4.77 4.63 0.14 4.69 0.08
74 5.10 5.11 0.01 5.01 0.09
75 4.27 4.13 0.14 4.32 0.05
77 4.00 4.01 0.01 4.19 0.19
78 4.96 4.88 0.08 4.63 0.33
79 4.70 4.38 0.32 4.37 0.33
80 4.82 5.09 0.27 4.82 0.00
81 5.10 4.89 0.22 4.80 0.30
84 5.05 5.04 0.01 5.28 0.23
86 5.00 4.98 0.02 5.13 0.13
88 5.82 5.66 0.16 5.63 0.19
89 4.36 4.36 0.00 4.37 0.01
90 4.62 4.81 0.19 4.90 0.28
(continued)
Table 5. Continued
CoMFA model CoMSIA model
Compound Exp. pCC50 Pred. pCC50 Residual Pred. pCC50 Residual
91 4.77 4.53 0.24 4.86 0.09
93 4.55 4.35 0.20 4.42 0.13
94 4.07 4.11 0.04 4.51 0.44
95 6.52 6.50 0.02 6.59 0.07
97 4.00 4.17 0.17 4.07 0.07
98 4.31 4.31 0.00 4.11 0.20
100 4.38 4.65 0.27 4.46 0.08
101 4.00 3.86 0.14 3.81 0.19
102 4.00 4.18 0.18 3.91 0.10
103 4.25 4.24 0.01 4.25 0.00
104 4.00 4.11 0.11 4.27 0.27
106 4.62 4.67 0.05 4.54 0.09
107 4.24 4.76 0.52 4.47 0.23
108 4.68 4.46 0.23 4.82 0.14
110 4.38 4.26 0.12 4.41 0.03
111 4.00 4.02 0.02 4.06 0.05
113 4.77 4.80 0.03 4.60 0.17
114 4.00 3.84 0.17 3.80 0.20
115 4.00 3.78 0.22 3.91 0.09
118 4.04 4.13 0.09 4.00 0.04
119 4.19 4.32 0.13 4.42 0.23
120 4.00 4.01 0.01 4.09 0.09
121 4.00 4.05 0.05 4.20 0.20
123 4.30 4.22 0.08 4.24 0.06
125 4.44 4.37 0.07 4.32 0.12
126 4.80 4.73 0.07 4.75 0.05
127 4.00 4.12 0.12 4.16 0.16
128 4.00 4.13 0.13 4.26 0.26
129 4.30 4.21 0.09 4.30 0.00
131 4.04 4.20 0.16 3.89 0.16
132 4.00 4.02 0.02 4.03 0.03
133 4.41 4.47 0.06 4.52 0.11
134 4.00 3.98 0.02 3.74 0.26
135 4.00 3.96 0.04 3.84 0.16
136 4.00 4.15 0.15 3.90 0.11
137 4.11 4.35 0.24 4.34 0.23
139 4.00 3.97 0.03 4.02 0.02
140 4.03 4.00 0.04 4.02 0.01
141 4.15 4.12 0.03 4.28 0.13
142 4.00 3.98 0.02 4.10 0.10
143 4.10 4.09 0.01 4.22 0.12
144 4.00 4.14 0.14 4.07 0.07
145 4.15 4.17 0.02 4.12 0.04
146 4.30 4.24 0.06 4.30 0.00
147 4.30 4.20 0.10 4.29 0.01
148 4.52 4.52 0.00 4.62 0.10
149 4.00 4.07 0.07 4.21 0.21
151 4.40 4.34 0.06 4.39 0.01
152 4.22 4.01 0.21 4.01 0.21
153 4.00 4.18 0.18 4.05 0.05
154 4.35 4.19 0.17 4.17 0.18
156 4.39 4.30 0.09 4.31 0.08
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Model a CoMFA and CoMSIA analyses (benzimidazoles anti-RSV
profile)
On the basis of model A, for all the data set, the steric contour
map predicts favourable substitutions at the benzimidazole pos-
ition 5 (green polyhedral), while the presence of any bulky group
at the position 6 results to be detrimental for the anti-RSV activity
(yellow polyhedral). The reliability of these information is sup-
ported by the inactivity of the 5,6-dichloro-benzimidazoles 44–49
and by the poor anti-RSV potency values of the 6-substituted ben-
zimidazoles 102 (pEC5054.20) and 103 (pEC5054.35).
Notably, the presence of a (even small) substituent linked to
the benzimidazole position 2 is favoured. Accordingly, compound
2 (R2¼ trifluoromethyl; pEC50¼4.66) display a better potency pro-
file if compared with the analogue 21 (R2¼ 4-bromobenzyl;
pEC50¼4.60), suggesting that a proper decoration on the benzimi-
dazole position 5 and at the R1 group could be successfully
accompanied by a small moiety in R2.
On the other hand, for those 2-substituted benzimidazoles
bearing a rigid phenyl group in R2 (such as 27, 29–31 and 102,
103), any further substitution at the ortho positions proves to be
encouraged, falling in a green area, while any other at the meta
and para ones are disfavoured, being surrounded by yellow poly-
hedra (Figure 2(a)).
These results are confirmed by the inactivity of compounds
40–43 (pEC50<4.00), which are poly-substituted at the phenyl
ring in R2. Moreover, for this series of compounds, any group
eventually placed in R1 results to be disfavoured. Indeed, also
compounds 97 (R1¼methyl; pEC50<4.00) and 98
(R1¼ cyclohexyl; pEC50<4.00) are not interesting as anti-RSV
agents.
On the contrary, those 2-substituted benzimidazoles bearing a
flexible group in R2 such as the benzyl one (compounds 5–24),
seems to properly affect the R1 substituent, moving it towards a
sterically favoured green area (Figure 2(b)). These results are sup-
ported by the better anti-RSV activity of compound 24
(R1¼ lupinyl-; pEC50¼5.05) with respect to compound 14
(R1¼N,N-diethylaminoethyl; pEC50¼4.12).
Notably, this information is also in accordance with the promis-
ing potency profile displayed within the series of 2-benzotriazolyl-
methyl-benzimidazoles, such as the analogues 120, 122 and 125
(pEC50¼7.22–7.52).
In addition, for the 2-benzyl-benzimidazoles here discussed, the
introduction of any decoration onto the benzyl ortho and para
positions is encouraged, as supported by the higher pEC50
value of 15 (R2¼ 4-iodophenyl-; pEC50¼4.40) than that of 14
(R2¼ 4-bromophenyl-; pEC50¼4.12) and by the pEC50 value of 11
(R2¼ 4-methoxyphenyl-; pEC50¼5.30).
Based on an overall analysis of the biological assays about the
whole dataset, those analogues bearing a (benzotriazol-1/2-
yl)methyl in R2 result to be the most promising. Accordingly, the
most of them display a successful behaviour with respect to
the 3D-QSAR maps. In particular, in the case of steric contribution,
the N(1)-substituted benzotriazoles much more properly fit the
two green favourable areas placed around the bicyclic ring
(Figure 3(a)). Accordingly, compound 2c (R2¼N(1)-benzotriazolyl;
pEC50¼5.64) shows a higher potency value than that of 28b
(R2¼ 4-iodophenyl-; pEC50¼4.40) and 27b (R2¼ 4-bromophenyl-;
pEC50¼4.12). In addition, the most effective compounds of all
these series (7c, 9c, 10c, 12c and 13c; pEC50¼7.00–7.70) are deco-
rated with a the (benzotriazol-1-yl)methyl moiety in R2.
Concerning the N(2)-substituted analogues, they display a quite
switched orientation, falling in any case within the allowed steric
contour map Figure 3(b)). Indeed, 148 (R2¼N(2)-benzotriazolyl;
pEC50¼7.52) shows a higher potency values than 20 (R2¼ 4-chlor-
obenzyl-; pEC50¼4.82).
Finally, it should be noticed that the presence of the N(1)-sub-
stituted benzotriazole ring rather than the N(2)-substituted benzo-
triazole promote a favourable positioning of the R1 group, such as
that shown by the homolupinyl chain of 126 and 148, depicted in
Figure 3. Indeed, the R1 of 126 much more effectively fall in a
beneficial green steric map.
Consequently, those compounds bearing a (benzotriazol-1-
yl)methyl nucleus in R2, such as 135 (pEC50¼5.15), 136
(pEC50¼5.92), 118 (pEC50¼6.52) and 126 (pEC50¼7.70), are char-
acterised by an increased anti-RSV activity values than the related
N(2)-benzotriazolyl-substituted analogues 150 (pEC50¼4.70), 138
(pEC50¼5.82), 140 (pEC50¼5.92) and 148 (pEC50¼7.52),
respectively.
On all these basis, the 3D-QSAR study confirms that the intro-
duction of an N(1)-substituted benzotriazole ring in R2 represents
the better choice at the benzimidazole position 2, in comparison
with the other chemical moieties explored within the dataset.
For model A, the electrostatic CoMFA map revealed for all the
molecules here investigated a blue area (beneficial for electroposi-
tive moieties) in proximity of the R3 substituent, while two other
polyhedral favourable for electropositive functions would involve a
(bulky) substituent eventually present in R1. Notably, these results
suggest the introduction of an electron-donor group onto the
benzimidazole position 5 (R3) rather than an electron-withdrawing
one, and also strongly promote the presence of a basic chain or
substituent properly connected with the benzimidazole N1 nitro-
gen atom.
In addition, a consistent blue region is placed near one of the
ortho positions of the R2 phenyl- and benzyl-substituted
Table 6. Model B CoMFA and CoMSIA analyses experimental and predicted
pCC50 values of the test set compounds.
CoMFA model CoMSIA model
Compound Exp. pCC50 Pred. pCC50 Residual Pred. pCC50 Residual
1 4.00 4.10 0.10 4.10 0.10
5 4.00 3.92 0.08 3.98 0.02
19 4.00 4.24 0.24 4.23 0.23
21 4.89 4.97 0.08 4.82 0.07
30 4.00 4.40 0.40 4.33 0.33
34 4.70 5.00 0.30 4.76 0.06
36 5.22 4.80 0.42 5.18 0.04
40 4.00 4.02 0.01 4.12 0.12
47 5.52 5.52 0.00 5.61 0.09
48 4.77 4.51 0.26 4.77 0.00
52 4.46 4.55 0.09 4.34 0.13
58 4.72 4.46 0.26 4.65 0.07
66 5.00 4.59 0.41 4.76 0.24
73 4.00 4.30 0.30 4.27 0.27
76 4.74 4.40 0.34 4.22 0.52
82 5.04 5.05 0.00 5.29 0.25
83 4.80 4.87 0.07 4.97 0.17
85 4.00 4.30 0.30 4.43 0.43
87 4.66 5.20 0.54 5.13 0.47
92 4.72 5.05 0.33 5.23 0.51
96 4.00 4.53 0.53 4.42 0.42
99 4.48 4.55 0.07 4.21 0.27
105 4.00 4.49 0.49 4.34 0.34
109 4.60 4.63 0.03 4.86 0.26
112 4.33 4.19 0.14 3.52 0.81
116 4.00 3.89 0.11 3.95 0.05
117 4.00 4.37 0.37 4.23 0.23
124 4.43 4.57 0.14 4.70 0.27
130 4.04 4.23 0.19 4.32 0.28
138 4.00 4.00 0.00 3.94 0.06
150 4.05 4.08 0.03 4.08 0.03
155 4.00 4.18 0.18 4.14 0.14
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benzimidazoles, as shown for compounds 44 and 11 in Figure 4.
The reliability of this information is confirmed by the poor activity
as anti-RSV agents of compounds 25 (R2¼ 2-nitrophenyl-;
pEC50¼4.40) and 49 (R2¼ 2,6-difluorophenyl-; pEC50<4.00), bear-
ing highly electron-withdrawing functions at the R2 phenyl ortho
positions.
On the other hand, the introduction of much more electro-
negative groups is recommended in proximity of the benzimida-
zole core and of the R2 phenyl and benzyl ring in R2 of 44 and
11. Consequently, the presence of electron-donor groups properly
decorating the aromatic R2 substituents results to be the most
beneficial. Indeed, among those compounds being unsubstituted
in R1, compound 11 (R2¼ 4-methoxybenzyl-; pEC50¼5.30) results
to be more effective than 48 (R2¼ 4-nitrophenyl-; pEC50<4.00)
and 49 (R2¼ 2,6-difluorophenyl-; pEC50<4.00).
In addition, contour maps predicted to be favoured for electro-
negative moieties are also shown around the electropositive core
eventually involving R1, and in the area placed between the
benzimidazole positions 6 and 7, even opening the possibility to
design new derivatives based on a tricyclic heteroaromatic ring in
place of the benzimidazole scaffold.
The most effective benzotriazole-based benzimidazoles
follow the aforementioned preferred electrostatic profile, being in
particular the N(1)-substituted benzotriazoles, rather than the
N(2)-substituted ones, more able to fulfil the electronegative area
occupied by the triazole ring, as depicted in Figure 5 around 126
and 148.
Moreover, the N(1)-substituted benzotriazoles better arrange
the basic core included in R1 towards the electropositive blue
area, being in accordance with the behaviour previously discussed
about the steric map. Interestingly, within the R1 basic moieties
here explored, the bulkier homolupinyl and the more flexible dia-
lkylaminoalkyl chains prove to be the most effective, optimising
any contacts with the CoMFA contour maps. Accordingly, com-
pound 126 is the most active of the whole series
(R1¼homolupinyl-; R2¼N(1)-benzotriazolyl; pEC50¼7.70).
Figure 2. Contour map of model A CoMFA steric regions are shown around the anti-RSV agent 44 (a) and 11 (b). The compounds are displayed in ball and stick mode.
Figure 3. Contour map of model A CoMFA steric regions are shown around the anti-RSV agent 126 (a) and 148 (b). The compounds are displayed in ball and stick
mode.
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The information derived by the CoMSIA hydrophobic map
highlights the relevance of lipophilic group in R3 (yellow regions),
while a small yellow polyhedral is also located in proximity of the
substituent eventually placed in R1. Conversely, more polar func-
tion (white regions) are predicted to be favoured at R4 and at the
R2 group, as shown around the phenyl and benzyl functions of 44
and 11 (Supplemental material S7).
The related hydrophobic map depicted around the benzotria-
zole-based benzimidazoles 126 and 148 points out the beneficial
role played by a high lipophilic substituent falling in R1, such as
the homolupinyl and N,N-diethylamino-ethyl ones (Figure 6).
The anti-RSV activity of benzimidazoles is enhanced by H-bond
acceptor functions (magenta polyhedral) near the ortho positions
of those analogues decorated with a phenyl group in R1, and at
the para position of those compounds bearing a benzyl moiety
(Supplemental material S8). On the contrary, it results to be disfav-
oured by any H-bond acceptor function eventually placed in R3 or
R4 (green areas).
Concerning the most promising benzotriazole-based benzimi-
dazoles, they also follow the aforementioned H-bond acceptor
preferences, being in particular the N(1)-substituted benzotriazoles,
rather than the N(2)-substituted ones, more able to arrange near
the favoured magenta area involving R2, as depicted in Figure 7.
Finally, the H-donor map discloses the relevance of favoured H-
bond donor groups (cyan polyhedral) only at the central core of
the area occupied by R1, being disfavoured at the surrounding
region (see Figure 8 depicted around 126 and 148 and
Supplemental material S9 concerning the phenyl and benzyl
Figure 4. Contour maps of model A CoMFA electrostatic regions are shown around the anti-RSV agents 44 (a) and 11 (b). The compounds are displayed in ball and
stick mode.
Figure 5. Contour maps of model A CoMFA electrostatic regions are shown around the anti-RSV agents 126 (a) and 148 (b). The compounds are displayed in ball and
stick mode.
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derivatives 44 and 11). Notably, this information is probably
related to the presence of the key basic chain, as we previously
highlight through the CoMFA electrostatic map. In particular, the
presence in R2 of the quinolizidine ring (lupinyl, epilupinyl and
honolupinyl) let the topology of the benzotriazole nucleus be
arranged in allowed conformations.
Model B CoMFA and CoMSIA analyses (benzimidazoles
cytotoxicity profile)
Model B CoMFA and CoMSIA analyses allowed us to highlight any
key feature eventually increasing the cytotoxicity against the
human MT-4 cell line.
In detail, the CoMFA steric map reveals, for all the
compounds, a probable higher toxicity profile related to the
presence of substituents near R3 or in the area placed between
the positions 6 and 7 of the benzimidazole ring (green area;
Figure 9), and also in the case of even small groups linked in R2
(compare compounds 2 (R3¼ trifluoromethyl-; pCC50¼4.66) and 4
(R2¼ cyclopentylmethyl; pCC50¼4.96) with 19 (R2¼ benzyl;
pCC50¼4.00)).
In the case of bulkier decorations in R2, the most flexible ones,
such as the benzyl-substituted benzimidazoles and the N(1)-substi-
tuted benzotriazoles-based derivatives, are projected towards yel-
low disfavoured regions, being therefore characterised by an
adequate safety profile. Conversely, the more rigid R2 phenyl- or
N(2)-substituted benzotriazoles-based analogues much more over-
lap a large green area, thus confirming their related possible cyto-
toxic role. Interestingly, the reliability of these results is supported
by the lower MT-4 pCC50 value of 11 (R2¼ 4-methoxybenzyl-;
pCC50¼4.54) if compared with the analogue 45 (R2¼ 4-methoxy-
phenyl-; pCC50¼6.00). On the other hand, based on the
Figure 6. Model A CoMSIA hydrophobic favoured and disfavoured regions are shown around the anti-RSV agents 126 (a) and 148 (b). The compounds are displayed in
ball and stick mode.
Figure 7. Model A CoMSIA H-bond acceptor favoured and disfavoured contour maps are displayed around benzimidazoles 126 (a) and 148 (b). The compounds are dis-
played in ball and stick mode.
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experimental data about the pattern of cytotoxicity investigated
within the benzotriazole analogues, they proved to display a quite
comparable profile.
Finally, for all the compounds, the introduction of a small sub-
stituent in R1 seems to be disfavoured in terms of pCC50 values.
Consequently, 6 (R1¼H; pCC50¼4.00) is found less toxic than 20
(R1¼ lupinyl-; pCC50¼5.22), and 9–10 (pCC50¼4.00), characterised
by a longer (basic) chain in R1, are more safe than 17
(pCC50¼4.40).
The CoMFA electrostatic contour map depicted in Figure 10
describes an overall incisive effect played by electropositive func-
tions included in a bulky R1 group, at the central core of the R2
substituent and in the area near R3. On the other hand, electro-
negative functions or electron-withdrawing moieties are favoured
as small R1 group, at the latter portion of R2 and in proximity of
the N2 nitrogen atom of the benzimidazole ring. In particular, the
R2 phenyl or benzyl analogues, further decorated with electro-
withdrawing or electron-rich functions especially at the para pos-
ition, represent those compounds which better fit the electrostatic
map, while the N(1)-substituted benzotriazoles, followed by the
N(2)-substituted benzotriazoles ones (lacking any further group on
the heterocyclic system) are projected elsewhere. Notably, these
information allow to retain the series including benzotriazole-
based decoration as the most safety ones with respect to the
others shown within the data set.
In agreement with these results, those compounds bearing
nitro-substituted benzyl moieties show high pCC50 values, such as
36, 37 (pCC50¼5.05–5.22).
Concerning the effect played by hydrophobic substitutions
around the benzimidazole scaffold with respect to the related
cytotoxicity profile, a critical role proves to be determined by lipo-
philic groups at the latter part of R1 and in R3 and R4 (Figure 11).
Figure 8. Model A CoMSIA H-bond donor favoured and disfavoured contour maps are shown around the anti-RSV agents 126 (a) and 148 (b). The compounds are dis-
played in ball and stick mode.
Figure 9. Contour map of model B CoMFA steric regions are shown around the anti-RSV agent 95 (a) and 156 (b). The compounds are displayed in ball and stick
mode.
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As a consequence, most of the compounds bearing a trifluoro-
methyl in R3 or a dichloro substitution at R3 and R4 led to quite
toxic compounds [see 44–49 (pCC50¼4.77–6.00)].
As we previously discussed for the electrostatic map, even in
this case the R2 phenyl- or benzyl-group analogues, rather than
the N(1)-substituted benzotriazoles- and N(2)-substituted benzo-
triazoles-based ones, are those that fully occupy the hydrophobic
map. In details, the R1 aromatic ring falls in a disfavoured hydro-
phobic region (white polyhedral), while any substituent eventually
placed at the phenyl- or benzyl-para position is also in contact
with a favourable yellow area. Interestingly, these data underline
that the benzimidazole cytotoxicity profile could be enhanced by
halogens in R3 and/or R4 and also by the presence of para-substi-
tuted phenyl- or benzyl-carboxamide groups in R2, falling this
moiety in a white area.
These results could be verified comparing 50 (pCC50¼4.00)
with 51–55 (pCC50¼4.00–4.51). Moreover, the presence of less
hydrophobic moieties in R1 also promotes the MT-4 pCC50 values
(compare 90 (R1¼ cyclohexyl-; pCC50¼4.62), 91 (R1¼ cyclohexyl-;
pCC50¼4.77) with 93 (R1¼ 1-adamantyl-; pCC50¼4.55), 94
(R1¼ 1-adamantyl-; pCC50¼4.07), respectively).
As shown in Figure 12, H-bond acceptor functions result detri-
mental for the benzimidazole selectivity index by increasing
cytotoxicity especially when they are placed around the (benzo-
triazol-2-yl) scaffold (magenta areas) and at the R2 phenyl- or ben-
zyl-para positions and, confirming the critical role of the
carboxamide function at this position.
Accordingly, also the H-donor contour map points out the pres-
ence of favoured (cyan areas) and disfavoured (purple areas)
donor functions in R2, representing the aforementioned carboxa-
mide moiety (Figure 13).
Based on an overall analysis of all the information coming from
model A and model B, all the three much more consistent series
of benzimidazoles, being substituted in R2 with a phenyl, benzyl
or benzotriazole ring, could be optimised through the introduction
of small group in R3 endowed with electropositive profile and a
less hydrophobic one than that displayed by the trifluoromethyl
group or chlorine atom. Concerning R1 it should be noticed that
model A underlines a key role played by H-bond acceptor moi-
eties included in bulky and hydrophobic appendages. On the con-
trary, the corresponding map developed around the MT-4 pCC50
values does not reveal any effect of H-bond acceptor functions at
this level. Consequently, all these series of derivatives should
be decorated with proper basic chain, such as the effective homo-
lupinyl and dialkylaminoalkyl ones (see the model A CoMFA
electrostatic results). In particular, new 2-phenyl-substituted
Figure 10. Contour maps of model B CoMFA electrostatic regions are shown around the anti-RSV agents 95 (a) and 156 (b), represented in stick mode.
Figure 11. Model B CoMSIA hydrophobic favoured and disfavoured regions are shown around the anti-RSV agents 95 (a) and 156 (b), represented in stick mode.
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benzimidazoles could particularly take advantage from such a dec-
oration in R1. Finally, the most promising substituent in R2
explored within the dataset proved to be the (benzotriazolyl)-
methyl one, opening the possibility to be optimised through a ser-
ies of isostere and/or by a proper selection of other R3
substituents.
Concerning this issue, it should be noticed that the anti-RSV
clinical candidate BMS-433771 was designed starting from a benzi-
midazolone-based compound, being bioisostere of the here dis-
cussed benzotriazol-1-yl moiety (Figure 14)34.
Notably, BMS-433771 qualitatively fulfils any key features rec-
ommended by the 3D-QSAR maps here proposed, also about the
substituent linked at the benzimidazole position 1, giving a further
validation of the applied computational protocol.
In this context, in order to gain a preliminary evaluation of the
reliability of the applied 3D-QSAR study, we synthesised two new
compounds exploring the effectiveness of the apolar and electro-
donor CH3 group in position 5 of the 2-[(benzotriazol-1-yl)methyl]-
benzimidazole framework.
Figure 12. Model B CoMSIA H-bond acceptor favoured and disfavoured contour maps are displayed around benzimidazoles 95 (a) and 156 (b), depicted in stick mode.
Figure 13. Model B CoMSIA H-bond donor favoured and disfavoured contour maps are shown around the anti-RSV agents 95 (a) and 156 (b), represented in stick
mode.
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Figure 14. Chemical structure of the anti-RSV agent BMS-433771.
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Biological data
As shown in Figure 15, the biological result of compounds 157
(pEC50¼ 7.52MT-4 pCC50<4.00) and 158 (pEC50¼ 7.52MT-4
pCC50¼4.39) confirmed the same anti-RSV activities with respect
to the previously synthesised prototype 120 (pEC50¼ 7.52MT-4
pCC50<4.00), characterised by a N,N-dimethylaminoethyl chain
linked at the benzimidazole position 1.
The presence of (quinolizidinyl)alkyl residue associated with the
5-Cl group of benzimidazole derivative 126 ring (pEC50¼ 7.70, MT-
4 pCC50¼ 4.35) contributed to the best activity against RSV, also
leading to an increased cytotoxicity. Notably, based on these data
and on the information coming from 3D-QSAR studies, the pro-
posed 5-methyl analogue 158 proved to be endowed with the
same potency, but lower toxicity against both the cell lines; under-
lying that 5-methyl substitution is fruitful for modulating the
safety profile (CC50/EC50).
Conclusions
The computational studies here presented highlight and discuss
the role played by the steric and electrostatic features and also by
hydrophobic, H-bond acceptor and donor moieties, in terms of
anti-RSV activity and cytotoxicity around the benzimidazole
scaffold.
Through focussed CoMFA and CoMSIA analyses, any pattern of
requirements able to specifically discriminate much more effective
antiviral agents endowed with an increased selectivity index was
addressed and deeply discussed. Based on information coming
from CoMFA and CoMSIA studies, we designed and synthesised
two new benzimidazole derivatives (157, 158) in order to verify
the reliability of computational studies. These compounds, being
actually endowed with the same high potency but improved
safety profiles, allowed us to pave the way for a more focussed
rational design process. A much more consistent number of more
drug-like anti-RSV agents will be disclosed in due course.
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